Literature DB >> 30836208

Perceived barriers to quitting cigarettes among hospitalized smokers with substance use disorders: A mixed methods study.

Hasmeena Kathuria1, Ryan G Seibert2, Vinson Cobb3, Nicole Herbst2, Zoe M Weinstein4, Minda Gowarty3, Reha Jhunjhunwala5, Eric D Helm3, Renda Soylemez Wiener6.   

Abstract

AIMS: Smoking cessation may promote long-term recovery in patients with substance use disorders (SUD). Yet smoking rates remain alarmingly high in this population. Using a sequential explanatory mixed methods approach, we examined smoking rates among hospitalized patients with SUD at a large safety-net hospital, and then characterized factors associated with smoking behaviors both quantitatively and qualitatively.
METHOD: We abstracted data from all hospital admissions (7/2016-6/2017) and determined demographics, substance use type, and other characteristics associated with cigarette use among those with SUD. We then conducted semi-structured qualitative interviews with 20 hospitalized SUD smokers. We analyzed transcripts to characterize factors that affect patients' smoking habits, focusing on the constructs of the Health Belief Model.
RESULTS: The prevalence of cigarette smoking among hospitalized smokers with SUD was three times higher than those without SUD. Qualitative analyses showed that patients perceived that smoking cigarettes was a less serious concern than other substances. Some patients feared that quitting cigarettes could negatively impact their recovery and perceived that clinicians do not prioritize treating tobacco dependence. Almost all patients with heroin use disorder described how cigarette use potentiated their heroin high. Many SUD patients are turning to vaping and e-cigarettes to quit smoking.
CONCLUSION: Hospitalized patients with SUD have disproportionately high smoking rates and perceive multiple barriers to quitting cigarettes. When designing and implementing smoking cessation interventions for hospitalized patients with SUD, policymakers should understand and take into account how patients with SUD perceive smoking-related health risks and how that influences their decision to quit smoking.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Addiction medicine; Heroin use; Hospitalized smokers; Smoking cessation; Substance use disorders; Tobacco dependence treatment

Mesh:

Year:  2019        PMID: 30836208     DOI: 10.1016/j.addbeh.2019.02.017

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  5 in total

1.  Effects of tobacco on affect and craving during opioid addiction recovery: An ecological momentary assessment study.

Authors:  Blythe E Rhodes; Nisha C Gottfredson
Journal:  Addict Behav       Date:  2020-02-17       Impact factor: 3.913

2.  A Content Analysis of U.S. Adults' Open-Ended Responses to E-Cigarette Risk Messages.

Authors:  Yachao Li; Bo Yang; Katherine Henderson; Lucy Popova
Journal:  Health Commun       Date:  2020-10-30

3.  Implementation and Outcomes of a Comprehensive Tobacco Free Workplace Program in Opioid Treatment Centers.

Authors:  Matthew Taing; Vijay Nitturi; Tzuan A Chen; Bryce Kyburz; Isabel Martinez Leal; Virmarie Correa-Fernández; Ezemenari M Obasi; Teresa Williams; Kathleen Casey; Daniel P O'Connor; Litty Koshy; Maggie Britton; Kelli Drenner; Lorraine R Reitzel
Journal:  Int J Environ Res Public Health       Date:  2021-12-26       Impact factor: 4.614

4.  Integrating Social Determinants of Health With Tobacco Treatment for Individuals With Opioid Use Disorder: Feasibility and Acceptability Study of Delivery Through Text Messaging.

Authors:  Hasmeena Kathuria; Divya Shankar; Vinson Cobb; Julia Newman; Katia Bulekova; Scott Werntz; Belinda Borrelli
Journal:  JMIR Form Res       Date:  2022-09-01

5.  LGB Tobacco Control: Do Health Belief Model Constructs Predict Tobacco Use Intentions Differently between LGB and Heterosexual Individuals?

Authors:  Yachao Li; Bo Yang; Bryan Chen
Journal:  Int J Environ Res Public Health       Date:  2021-06-30       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.